Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

With over 5 million concussions occurring annually in the U.S. alone, there is a significant unmet need for effective diagnostic and therapeutic solutions. This partnership positions Oragenics and ...

Oragenics (OGEN) announced a strategic partnership with BRAINBox Solutions. This collaboration seeks to develop the first intranasal therapy ...

Investment analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock. Oragenics Stock ...

European shares were mixed today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX 40 slipped 0.1% and France's CAC 40 fell ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

For more information, see our expert panel. Stock trading apps empower investors to buy and sell securities directly from the convenience of their mobile devices. The best stock trading apps ...

All the worries sent investors toward bonds, which can be safer investments than any stock. The rush pushed the yield of the 10-year Treasury down to 4.52% from 4.62% late Friday. It’s a sharp ...